{"id":1695,"date":"2025-06-23T13:08:03","date_gmt":"2025-06-23T13:08:03","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:37:40","modified_gmt":"2026-06-26T18:37:40","slug":"9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/","title":{"rendered":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program"},"content":{"rendered":"\n<p><strong>Quebec City, QC, June 23, 2025<\/strong>&nbsp;\u2013 9Bio Therapeutics, a biotechnology company engineering conditionally active biologics to treat cancer, is proud to announce a strategic investment from the Merck Global Health Innovation Fund (Merck GHI) and CQDM. The funding will accelerate the development of 9Bio\u2019s computationally guided discovery platform and pipeline of tumor-selective therapies.<\/p>\n\n\n\n<p>The investment is part of 9Bio\u2019s selection to the competitive Merck Digital Sciences Studio (MDSS) program, which provides capital and access to global expertise to high-potential biotech startups. Through this initiative, 9Bio gains not only financial backing, but also direct exposure to Merck\u2019s experts, decision-makers, and international network \u2013 paving the way for long-term collaborations. The program is delivered in partnership with Centech, a leading business incubator and innovation hub in Montreal, Quebec.<\/p>\n\n\n\n<p>\u201cBeing selected by Merck and CQDM highlights the growing interest in novel approaches to oncology\u201d said Henrique de Carvalho, Co-Founder &amp; CEO of 9Bio Therapeutics. \u201cTheir support reinforces confidence in our platform and our vision to develop the next generation of cancer treatments for patients who have few or no options today.\u201d<\/p>\n\n\n\n<p>9Bio\u2019s approach integrates computational biology and structural modeling to engineer therapies that can selectively activate at the tumor site \u2013 offering a potential paradigm shift in how biologics are designed and delivered.<\/p>\n\n\n\n<p>\u201cThe role of computational biology is evolving beyond tools like machine learning to newer language learning models and neural networks, and being on the forefront of that evolution across regions has the potential to positively impact drug development for the pharma industry,\u201d said David Rubin, Managing Director at Merck Global Health Innovation Fund.<\/p>\n\n\n\n<p>Philipe Gobeil, PhD, Co-Founder, President &amp; CSO of 9Bio added: \u201cWe\u2019re building a platform that has the potential to redefine the way biologics are designed and delivered in oncology \u2013 and this partnership accelerates our path toward that goal.\u201d<\/p>\n\n\n\n<p>With the backing of a leading global healthcare investor and CQDM, 9Bio is well positioned to advance its platform and pipeline toward the next phase of development. Participation in the MDSS program is non-exclusive, allowing 9Bio to continue building strategic relationships with other pharmaceutical partners and collaborators across the industry. The company is currently in discussions with additional investors to expand its funding round and further accelerate progress toward key preclinical and translational milestones.<\/p>\n\n\n\n<p>Read the official Merck press release&nbsp;<a href=\"https:\/\/www.merck.ca\/en\/newsroom\/merck-digital-sciences-studio-opens-in-canada-to-accelerate-biopharmaceutical-innovation\/\" rel=\"noreferrer noopener\" target=\"_blank\">here<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>About 9Bio Therapeutics<\/strong><\/p>\n\n\n\n<p>9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes two discovery-stage therapies: an antibody-drug conjugate (ADC) targeting chemoresistant tumor cells and an ADC targeting tumor-subverted immune cells.<\/p>\n\n\n\n<p><strong>About Merck Digital Science Studio<\/strong><\/p>\n\n\n\n<p>The Merck Digital Sciences Studio (MDS Studio, or MDSS) is an accelerator program providing mentorship, coaching, training, support, community, and investment to enable the next generation of innovative technologies for drug discovery and development. We invest in disruptive and innovative startups in digital biopharma via a SAFE (Simple Agreement for Future Equity). The MDS Studio\u2019s unique design and network empowers startups to engage with industry leading partners, who take an active role in development. Learn more by visiting&nbsp;<a href=\"http:\/\/www.mds.studio\/\" rel=\"noreferrer noopener\" target=\"_blank\">www.mds.studio<\/a>.<\/p>\n\n\n\n<p><strong>About Merck<\/strong><\/p>\n\n\n\n<p>At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit&nbsp;<a href=\"http:\/\/www.merck.ca\/\" rel=\"noreferrer noopener\" target=\"_blank\">www.merck.ca<\/a>&nbsp;and connect with us on&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck-canada\/\" rel=\"noreferrer noopener\" target=\"_blank\">LinkedIn<\/a>&nbsp;@MerckCanada.<\/p>\n\n\n\n<p><strong>About the CQDM<\/strong><\/p>\n\n\n\n<p><em>Biopharma Innovation Facilitator<\/em><\/p>\n\n\n\n<p>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Qu\u00e9bec and Canadian economy. For more information, consult our website&nbsp;<a href=\"https:\/\/cqdm.org\/en\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/cqdm.org\/en\/<\/a>&nbsp;and join us on Twitter\/X&nbsp;<a href=\"https:\/\/x.com\/CQDM_Canada\" rel=\"noreferrer noopener\" target=\"_blank\">@CQDM_Canada<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" rel=\"noreferrer noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/9bio.ca\/news\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/\">Read the original press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Quebec City, QC, June 23, 2025&nbsp;\u2013 9Bio Therapeutics, a biotechnology company engineering conditionally active biologics to treat cancer, is proud to announce a strategic investment from the Merck Global Health [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1697,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[89],"class_list":["post-1695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare\" \/>\n<meta property=\"og:description\" content=\"Quebec City, QC, June 23, 2025&nbsp;\u2013 9Bio Therapeutics, a biotechnology company engineering conditionally active biologics to treat cancer, is proud to announce a strategic investment from the Merck Global Health [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T13:08:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:37:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program\",\"datePublished\":\"2025-06-23T13:08:03+00:00\",\"dateModified\":\"2026-06-26T18:37:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/\"},\"wordCount\":791,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/\",\"name\":\"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"datePublished\":\"2025-06-23T13:08:03+00:00\",\"dateModified\":\"2026-06-26T18:37:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare","og_description":"Quebec City, QC, June 23, 2025&nbsp;\u2013 9Bio Therapeutics, a biotechnology company engineering conditionally active biologics to treat cancer, is proud to announce a strategic investment from the Merck Global Health [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/","og_site_name":"adMare","article_published_time":"2025-06-23T13:08:03+00:00","article_modified_time":"2026-06-26T18:37:40+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program","datePublished":"2025-06-23T13:08:03+00:00","dateModified":"2026-06-26T18:37:40+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/"},"wordCount":791,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/","name":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","datePublished":"2025-06-23T13:08:03+00:00","dateModified":"2026-06-26T18:37:40+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1695"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1695\/revisions"}],"predecessor-version":[{"id":1696,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1695\/revisions\/1696"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1697"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1695"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}